B- and T-lymphocyte Responses to an Immunodominant Epitope of Human Immunodeficiency Virus

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1988 Aug 1

PMID 3260630

Citations 28

Authors

R D Schrier

J W Gnann Jr

A J Langlois

K Shriver

J A Nelson

M B Oldstone

Affiliations

Soon will be listed here.

Abstract

Using synthetic peptides, we characterized the B-lymphocyte (antibody) and T-lymphocyte (proliferation) responses to an immunodominant epitope of human immunodeficiency virus type 1 (HIV-1) located near the amino-terminal end of the transmembrane glycoprotein (env amino acids 598 to 609). Both immunoglobulin M (IgM) and IgG antibodies against this epitope appeared early after primary infection with HIV-1. In an animal model, the IgG response to a synthetic peptide derived from this sequence was T-helper-cell dependent, whereas the IgM response was T-cell independent. In addition, antibody generated by immunization with this peptide had HIV-1-neutralizing activity. Greater than 99% (201 of 203) of patients infected with HIV-1 generated antibody to this peptide in vivo; however, only 24% (7 of 29) had T cells that proliferated in response to this peptide in vitro. These observations suggest that different HIV-1 gp41 epitopes elicit B-cell and T-cell immune responses.

Citing Articles

Vaccination against the Koala Retrovirus (KoRV): Problems and Strategies.

Denner J Animals (Basel). 2021; 11(12).

PMID: 34944329 PMC: 8697897. DOI: 10.3390/ani11123555.

Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope.

Penn-Nicholson A, Han D, Kim S, Park H, Ansari R, Montefiori D Virology. 2007; 372(2):442-56.

PMID: 18068750 PMC: 2293309. DOI: 10.1016/j.virol.2007.11.009.

Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state.

Kim M, Qiao Z, Yu J, Montefiori D, Reinherz E Vaccine. 2006; 25(27):5102-14.

PMID: 17055621 PMC: 2705924. DOI: 10.1016/j.vaccine.2006.09.071.

Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein.

Zhan X, Slobod K, Surman S, Brown S, Lockey T, Coleclough C J Virol. 2003; 77(7):4231-6.

PMID: 12634380 PMC: 150625. DOI: 10.1128/jvi.77.7.4231-4236.2003.

Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques.

Polacino P, Stallard V, Klaniecki J, Pennathur S, Montefiori D, Langlois A J Virol. 1999; 73(10):8201-15.

PMID: 10482571 PMC: 112838. DOI: 10.1128/JVI.73.10.8201-8215.1999.

References

Modrow S, Hahn B, Shaw G, Gallo R, Wong-Staal F, Wolf H . Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J Virol. 1987; 61(2):570-8. PMC: 253982. DOI: 10.1128/JVI.61.2.570-578.1987. View

Matthews T, Langlois A, Robey W, Chang N, Gallo R, Fischinger P . Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A. 1986; 83(24):9709-13. PMC: 387210. DOI: 10.1073/pnas.83.24.9709. View

Guyader M, Emerman M, Sonigo P, Clavel F, Montagnier L, Alizon M . Genome organization and transactivation of the human immunodeficiency virus type 2. Nature. 1987; 326(6114):662-9. DOI: 10.1038/326662a0. View

Cooper D, Imrie A, Penny R . Antibody response to human immunodeficiency virus after primary infection. J Infect Dis. 1987; 155(6):1113-8. DOI: 10.1093/infdis/155.6.1113. View

Wahren B, Biberfeld G, Moberg L, Sonnerborg A, Ljungman P, Werner A . Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol. 1987; 61(6):2017-23. PMC: 254211. DOI: 10.1128/JVI.61.6.2017-2023.1987. View

Ho D, Sarngadharan M, Hirsch M, Schooley R, ROTA T, Kennedy R . Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol. 1987; 61(6):2024-8. PMC: 254212. DOI: 10.1128/JVI.61.6.2024-2028.1987. View

Gosting L, McClure J, Dickinson E, Watanabe S, Shriver K, Goldstein L . Monoclonal antibodies to gp110 and gp41 of human immunodeficiency virus. J Clin Microbiol. 1987; 25(5):845-8. PMC: 266101. DOI: 10.1128/jcm.25.5.845-848.1987. View

Robert-Guroff M, Giardina P, Robey W, Jennings A, Naugle C, Akbar A . HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with beta-thalassemia. J Immunol. 1987; 138(11):3731-6. View

Cease K, Margalit H, Cornette J, Putney S, Robey W, Ouyang C . Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci U S A. 1987; 84(12):4249-53. PMC: 305062. DOI: 10.1073/pnas.84.12.4249. View

10.

Gnann Jr J, Schwimmbeck P, Nelson J, Truax A, Oldstone M . Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J Infect Dis. 1987; 156(2):261-7. DOI: 10.1093/infdis/156.2.261. View

11.

Prince A, Pascual D, Kosolapov L, Kurokawa D, Baker L, Rubinstein P . Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus. J Infect Dis. 1987; 156(2):268-72. DOI: 10.1093/infdis/156.2.268. View

12.

Gnann Jr J, Nelson J, Oldstone M . Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol. 1987; 61(8):2639-41. PMC: 255715. DOI: 10.1128/JVI.61.8.2639-2641.1987. View

13.

Walker B, Chakrabarti S, Moss B, Paradis T, Flynn T, Durno A . HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987; 328(6128):345-8. DOI: 10.1038/328345a0. View

14.

Krohn K, Robey W, Putney S, Arthur L, Nara P, Fischinger P . Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men. Proc Natl Acad Sci U S A. 1987; 84(14):4994-8. PMC: 305233. DOI: 10.1073/pnas.84.14.4994. View

15.

Zarling J, Eichberg J, Moran P, McClure J, Sridhar P, Hu S . Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins. J Immunol. 1987; 139(4):988-90. View

16.

Hu S, Fultz P, McClure H, Eichberg J, Thomas E, Zarling J . Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature. 1987; 328(6132):721-3. DOI: 10.1038/328721a0. View

17.

Lasky L, Nakamura G, Smith D, Fennie C, Shimasaki C, Patzer E . Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell. 1987; 50(6):975-85. DOI: 10.1016/0092-8674(87)90524-1. View

18.

Smith R, Naso R, Rosen J, Whalley A, Hom Y, Hoey K . Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection. J Clin Microbiol. 1987; 25(8):1498-504. PMC: 269257. DOI: 10.1128/jcm.25.8.1498-1504.1987. View

19.

Gnann Jr J, McCormick J, Mitchell S, Nelson J, Oldstone M . Synthetic peptide immunoassay distinguishes HIV type 1 and HIV type 2 infections. Science. 1987; 237(4820):1346-9. DOI: 10.1126/science.2888192. View

20.

Kowalski M, Potz J, Basiripour L, Dorfman T, Goh W, Terwilliger E . Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science. 1987; 237(4820):1351-5. DOI: 10.1126/science.3629244. View